Literature DB >> 12442682

Position of COMT inhibition in the treatment of Parkinson's disease.

Ariel Gordin1, Seppo Kaakkola, Heikki Teräväinen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12442682

Source DB:  PubMed          Journal:  Adv Neurol        ISSN： 0091-3952


× No keyword cloud information.
  4 in total

1.  Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study.

Authors:  Heinz Reichmann; Andrew Lees; José-Francisco Rocha; Diogo Magalhães; Patrício Soares-da-Silva
Journal:  Transl Neurodegener       Date:  2020-03-04       Impact factor: 8.014

2.  Clinical Pharmacology of Entacapone (Comtan) From the FDA Reviewer.

Authors:  Sam Habet
Journal:  Int J Neuropsychopharmacol       Date:  2022-08-04       Impact factor: 5.678

3.  A structure-activity relationship study of catechol-O-methyltransferase inhibitors combining molecular docking and 3D QSAR methods.

Authors:  Anu J Tervo; Tommi H Nyrönen; Toni Rönkkö; Antti Poso
Journal:  J Comput Aided Mol Des       Date:  2003-12       Impact factor: 3.686

4.  Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study.

Authors:  Heinz Reichmann; Andrew Lees; José-Francisco Rocha; Diogo Magalhães; Patrício Soares-da-Silva
Journal:  Transl Neurodegener       Date:  2020-03-04       Impact factor: 8.014
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.